Skip to content
Medicines & Healthcare products Regulatory Agency
The National Institute for Biological Standards and Control

Confidence in biological medicines

  • Stay connected
  • Shopping Basket
  • Pay Now
  • Login / Register
  • Home
  • Products
  • Standardisation
  • Control testing
  • Science and research
  • Expert services
  • About us
  • QE2
  • Advanced therapies
  • Virology
  • Bacteriology
  • Biotherapeutics
  • Analytical sciences
  • Infectious Disease Diagnostics
  • A to Z listing
  • Publications
  • Home  /  
  • Science and research  /  
  • Virology  /  
  • Influenza Resource Centre  /  
  • Full reagent update

Reagent update

Current availability from NIBSC of candidate influenza vaccine viruses, SRD reagents and neuraminidase reagents for use in the 2023-24 Northern hemisphere season and 2023 Southern hemisphere season (See below for pricing information).

More information can be found in the Influenza Resource Centre pages

Update 151 - 28 February 2023


Candidate influenza viruses for use in the Northern hemisphere 2023-241

Candidate influenza vaccine viruses

NIBSC code

H1N1

 

A/Victoria/4879/2022

22/316

IVR-238 ressortant derived from A/Victoria/4879/2022

22/318

H3N2

 

A/Darwin/9/2021

21/214

NIB-126 reassortant derived from A/Darwin/9/2021

21/228

IVR-228 reassortant derived from A/Darwin/9/2021

21/246

X-369A ressortant derived from A/Darwin/9/2021

21/384

SAN-010 reassortant derived from A/Darwin/9/2021

21/306

A/Darwin/6/2021

21/212

NIB-127 reassortant derived from A/Darwin/6/2021

21/226

IVR-227 reassortant derived from A/Darwin/6/2021

21/204

X-367A reassortant derived from A/Darwin/6/2021

21/382

A/Michigan/173/2020

21/298

B (Victoria lineage)

 

B/Austria/1359417/2021

21/224

BVR-26 reassortant derived from B/Austria/1359417/2021

21/218

B/Michigan/01/2021

21/244

B/Singapore/WUH4618/2021

21/242

B/Guangdong-Zhenjiang/1516/2021

21/388

B (Yamagata lineage)

 

B/Phuket/3073/2013 wild type virus

21/132

B/Brisbane/9/2014 wild type virus

21/352

B/Utah/9/2014 wild type virus

14/320 & 21/348

NYMC BX-57 reassortant derived from

B/Hong Kong/3417/2014

20/134

NYMC BX-59A reassortant derived from B/California/12/2015

15/274 & 21/350

NYMC BX-59B reassortant derived from B/California/12/2015

15/294

NYMC BX-63 reassortant derived from B/Arizona/10/2015

17/124

NYMC BX-63A reassortant derived from B/Arizona/10/2015

17/126

1Recommendations announced for influenza vaccine composition for the 2023-2024 northern hemisphere influenza season (who.int)

Candidate influenza viruses for use in the Northern hemisphere 2023-241

Reagents for influenza vaccine standardisation

NIBSC code

H1N1

 

Antigen

 To de defined               

Antiserum

 To be defined

H3N2

 

A/Darwin/9/2021 (SAN-010) antigen

21/320

A/Darwin/9/2021 (IVR-228) antigen

21/318

A/Darwin/6/2021 (IVR-227) antigen

21/314

A/Darwin/9/2021 - like antiserum

21/324

B (Victoria lineage)

 

B/Austria/1359417/2021 (BVR-26) antigen

21/316

B/Michigan/01/2021 antigen

21/330

B/Austria/1359417/2021 - like antiserum

21/326

B (Yamagata lineage)

 

B/Phuket/3073/2013 antigen

21/136

B/Utah/9/2014 (cell derived) antigen

15/100

B/Singapore/INFTT-16-0610/2016 (cell derived) antigen

19/308

B/Phuket/3073/2013 - like antiserum

19/322

1Recommendations announced for influenza vaccine composition for the 2023-2024 northern hemisphere influenza season (who.int)

Neuraminidase reagents

NIBSC code

N1

 

NA antiserum prepared from A/California/7/2009

10/218

NA antiserum prepared from A/New Caledonia/20/99

04/230

N2

 

NA antiserum prepared from A/Victoria/361/2011

14/144

NA antiserum prepared from A/South Australia/34/2019

19/320

B

 

NA antiserum prepared from B/Jiangsu/10/2003

04/228

NA antiserum prepared from B/Malaysia/2506/2004

05/252

NA antiserum prepared for B/Florida/4/2006

09/316

(please contact for availability)

NA antiserum prepared from B/Phuket/3073/2013

21/322

Candidate influenza viruses for use in the Southern hemisphere 20232

Candidate influenza vaccine viruses

NIBSC code

H1N1

 

A/Sydney/5/2021

22/200

SAN-013 reassortant derived from A/Sydney/5/2021

22/142

CBER-48A reassortant derived from A/Sydney/5/2021

22/214

IVR-235 reassortant derived from A/Sydney/175/2022

22/234

H3N2

 

A/Darwin/9/2021

21/214

NIB-126 reassortant derived from A/Darwin/9/2021

21/228

IVR-228 reassortant derived from A/Darwin/9/2021

21/246

X-369A ressortant derived from A/Darwin/9/2021

21/384

SAN-010 reassortant derived from A/Darwin/9/2021

21/306

A/Darwin/6/2021

21/212

NIB-127 reassortant derived from A/Darwin/6/2021

21/226

IVR-227 reassortant derived from A/Darwin/6/2021

21/204

X-367A reassortant derived from A/Darwin/6/2021

21/382

A/Michigan/173/2020

21/298

B (Victoria Lineage)

 

B/Austria/1359417/2021

21/224

BVR-26 reassortant derived from B/Austria/1359417/2021

21/218

B/Michigan/01/2021

21/244

B/Singapore/WUH4618/2021

21/242

B/Guangdong-Zhenjiang/1516/2021

21/388

B (Yamagata lineage)

 

B/Phuket/3073/2013 wild type virus

21/132

B/Brisbane/9/2014 wild type virus

21/352

B/Utah/9/2014 wild type virus

14/320 & 21/348

NYMC BX-57 reassortant derived from

B/Hong Kong/3417/2014

20/134

NYMC BX-59A reassortant derived from B/California/12/2015

15/274 & 21/350

NYMC BX-59B reassortant derived from B/California/12/2015

15/294

NYMC BX-63 reassortant derived from B/Arizona/10/2015

17/124

NYMC BX-63A reassortant derived from B/Arizona/10/2015

17/126

2New recommendations for the composition of influenza vaccines in 2023 for the southern hemisphere (who.int)

SRD reagents for use in the Southern hemisphere 20232

(For H3N2 subtype and B Victoria and Yamagata lineage reagents please see tables for Northern hemisphere 2023-2024 above)

Reagents for influenza vaccine standardisation

NIBSC code

H1N1

 

A/Victoria/2570/2019 (IVR-215) antigen

22/100

A/Victoria/2570/2019 - like antiserum

21/210

2New recommendations for the composition of influenza vaccines in 2023 for the southern hemisphere (who.int)

Pricing information

Viruses are free of charge (normally a maximum of two vials per recipient), but customers are expected to pay shipping and packing costs. Reagents for Single Radial Diffusion assay are subject to a handling fee as stated on the product information page, plus shipping and packing costs. Approved National Control Laboratories for human health are exempt from the handling fee.

Calibration of Reagents for Influenza vaccine standardisation

Reference antigens and antiserum reagents for the standardization of vaccines are produced by the following WHO laboratories:

Essential Regulatory Laboratories (ERL)

National Institute for Biological Standards and Control (NIBSC), UK

Center for Biologics Evaluation and Research (CBER), USA

National Institute for Infectious Disease (NIID), Japan

Therapeutic Goods Administration (TGA), Australia

Key staff

Othmar Engelhardt, Principal Scientist
Jason Long, Principal Scientist
Francesco Gubinelli, Senior Scientist
Basma Bahsoun, Scientist
Victoria Bailey, Scientist
Sitara Dubey, Scientist
Elli Elenoglou, Scientist
Kajetan Rakowski, Scientist

  • Careers
  • Terms and conditions
  • Accessibility
  • Privacy notice
  • Cookies
  • Sitemap